In the light of changing anti-microbial resistance pattern, the understanding of the local antibiogram is essential in the antibiotic selection procedures and preparation of hospital antibiotic policy. Aim: This retrospective study was aimed to analyze the antibacterial susceptibility pattern of major isolates from ICU and IPD. Materials and Methods: Antimicrobial susceptibility testing was done for a total of 565 Gramnegative isolates including E. coli, K. pnuemoniae, A. baumannnii and P. aeruginosa from ICU and IPD patients enrolled between July 2016 to December 2016. Results: The majority of the isolates were reported from urine samples (52%) in IPD and sputum (59%) in ICU. The susceptibility to BL/BLI was 50-75% in IPD patients and Carbapenem Khandait et al.; MRJI, 29(2): 1-10, 2019; Article no.MRJI.51575 2 susceptibility was reported in more than 75% except P. aeruginosa. In ICU patients, the betalactam/beta-lactam inhibitor (BL/BLI) susceptibility ranged between 20-60% and the carbapenem susceptibility was around 40%-75%. The susceptibility of CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was almost similar to minocycline and amikacin ranging from 50-90% against different species. Compared to carbapenems, the CSE-1034 performed overall better than carbapenems against P. aeruginosa and A. baumannii and was comparable to carbapenems against Enterobacteriaceae. The susceptibility of colistin ranged from 92-97% in both IPD and ICU isolates. Conclusion: Considering the value of carbapenems and colistin as the last option for multi-drug resistant (MDR) bacterial infections, irrational prescription of these drugs should be stopped. The use of ampicillin-sulbactam, cefepime and gentamicin from 1 st line antibiotics in ICU patients can help to reduce the load on 2 nd line antibiotics. Among 2 nd line drugs, CSE-1034 along with amikacin should be an empirical choice of treatment for bacterial infections where the 1st line drugs are suspected to fail and the need of carbapenems arises.
INTRODUCTION
Antimicrobial resistance (AMR) is an increasingly recognized concern across the globe [1, 2] . It has been estimated that by 2050, 10 million lives a year will be at risk due to emergence of infections by multi-drug resistant (MDR) pathogens [3] . The US Center for Disease Control and Prevention (CDC) estimates that antibiotic resistance is responsible for more than 2 million infections and 23,000 deaths each year in the United States at a direct cost of $20 billion and additional productivity loss of $35 billion [4] . Overuse of antibiotics is considered as the prime reason for the rise in antimicrobial resistance. Various countries like BRICS (Brazil, Russia, India, China and South Africa) account for 3/4 th of total usage of antibiotics in the world [5] . Mechanisms behind antimicrobial resistance in these microorganisms include production of extended spectrum ß lactamases (ESBL) and metallo ß lactamase (MBL), changes in membrane permeability, over-expression of efflux pump and production of biofilms [6] .
Infections due to MDR pathogens is not limited to particular organ system and includes wide range of infections including urinary tract infection, blood stream infection, intra-abdominal infection, lower respiratory tract infection, skin and soft tissue infection, etc [7, 8] . Considering the rise in the incidence of multi-drug resistant pathogens globally, there is a need to study the prevalence and susceptibility profile of various pathogens on a regular basis [9, 10] . A routine surveillance helps to establish, modify the treatment guidelines and guide the clinicians for the prescription of appropriate empirical antimicrobial therapy. In light of this, we aimed to conduct a microbial surveillance study in Paras hospital, India to study the susceptibility profile of the major pathogens including E. coli, K. pnuemoniae, A. baumannii and P. aeruginosa culture isolates from ICU and IPD patients against first and second line of antibiotics.
MATERIALS AND METHODS

Sample Collection
A retrospective analysis study on antibiotic susceptibility data obtained during July 2016 to December 2016 was conducted at Dept. of Microbiology, Paras hospital, Gurgaon, Haryana. The study was approved by the ethical committee of the hospital. Various clinical samples (N=565) used for pathogen isolation were obtained from patients with urinary tract infections, respiratory tract infections, blood stream infections and gastro-intestinal infections. The different clinical samples used for pathogen isolation were urine, blood, sputum, endotracheal secretions, BAL, sputum, TT secretions, ascitic fluids, bile and samples from drains.
The collection and processing of the samples were done as per common Standard Operating Procedures.
Isolation and Processing of Samples
All the samples were collected aseptically in sterile containers and inoculated on the different selective and non-selective culture media as per the standard microbiological techniques. Details of the culture media used for the isolation of pathogens from various clinical samples are given in Table 1 . Blood samples collected in brain heart infusion (BHI) broth and incubated overnight at 37°C. These samples were further sub-cultured on the selective or non-selective media and incubated aerobically overnight at 37°C. Organisms were identified on the basis of colony morphology, gram staining, motility and biochemical reactions. Biochemical reactions were performed by inoculating the bacterial colony in a nutrient broth at 37°C for 2-3 hours [11] .
Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing was done by Broth micro-dilution method using Vitek 2 as recommended by the CLSI guidelines (2016) [12] . The disc diffusion method [13] was used to determine the susceptibility of CSE-1034. The statistical analysis was done using graph-pad. 
RESULTS
Sample Collection and Identification of Pathogens
Antibiotic Susceptibility Profile of Clinical Isolates from IPD Patients
Antibiogram profile of all the pathogens obtained from IPD clinical specimens is presented in Tables 3 & 4 . Data suggested that the susceptibility observed to all first line antibiotics were less than 50% in IPD patients except ampicillin-sulbactam, cefepime and gentamicin. The Enterobacteriaceae family exhibited 20-46% susceptibility to aztreonam and amoxycillinclavulanate whereas the susceptibility of other Gram negative bacilli was negligible.
The susceptibility to ampicillin-sulbactam was more than 50% for all the species with lowest of 61.54% against K. Pneumoniae and highest of 82.9% against E. coli. K. pneumoniae showed the highest susceptibility to gentamicin whereas the lowest was shown by A. baumannii (59.6%). Among cephalosporins, the highest susceptibility was observed towards fourth generation cephalosporin "cefepime". Among fluoroquinolones, 45-55% of all isolates were susceptible to both ciprofloxacin and levofloxacin except K. pneumoniae and P. aeruginosa.
Regarding second line drugs, an enhanced susceptibility was observed in IPD patients. Data suggested that the clinical isolates of E. coli showed comparatively higher susceptibility (62-94%) to all the antibiotics and the lowest was reported in P. aeruginosa (55-83.7%). The susceptibility of E. coli was lowest to betalactam/beta-lactam inhibitor combinations, and was highest to colistin, polymyxin and tigecycline (95-96%). Among carbapenems, an average of 56% susceptibility was reported against P. aeruginosa, 75% against A. baumannii, whereas 82-87% of K. pneumoniae and E. coli were reported susceptible to carbapenems.
The susceptibility rates of CSE-1034 against K. pneumoniae, E. coli, A. baumannii and P. aeruginosa were 88.9%, 88%, 85% and 75% respectively. The drugs which showed more than 90% susceptibility included minocycline against K. pneumoniae and E. coli (90% each), colistin against all the isolates (92-97%), polymyxin B against E. coli (95%). 
Antibiotic Susceptibility Profile of Clinical Isolates from ICU Patients
Antibiogram profile of the pathogens obtained from ICU patients is presented in Table 5 and Table 6 . The average susceptibility rate of first line of antibiotics against all pathogens was less than 10% except gentamicin, ampicillinsulbactam and cefepime which was similar to IPD patients. The susceptibility rate to ampicillinsulbactam was 60-70%, 63-77% to gentamicin and 61-78% to cefepime. Among second line of antibiotics tested, the overall susceptibility of all isolates to 2 nd line drugs tested was lower by 10-20% in ICU patients except K. pneumoniae. A big drop in the susceptibility rate by 40-50% was observed against K. pneumoniae in ICU patients. Among BL/BLIs, K. pneumoniae exhibited almost similar susceptibility to cefoperazone-sulbactam and pip-taz (21-27%) and 60% to cefepimetazobactam. The susceptibility rates of A. baumannii and E. coli were 41-55% and P. aeruginosa was 40-60%. Interestingly, E. coli showed highest susceptibility to pip-taz and P. aeruginosa showed similar susceptibility to cefoperazone-sulbactam and cefepimetazobactam.
Among carbapenems, 40% susceptibility was observed against K. pneumoniae and P. aeruginosa and 70-77% against A. baumannii and E. coli. The susceptibility rates of different pathogens to CSE-1034 were almost similar to amikacin and minocycline. Among all the pathogens tested, K. pneumoniae exhibited least susceptibility of 40-50% to all the drugs tested whereas the susceptibility observed against all other pathogens was between 70-83%. Among peptides, the susceptibility rate of 92-97% was reported towards colistin whereas the average susceptibility of 86% was reported towards polymyxin-B by all pathogens except P. aeruginosa (47.9%). The susceptibility of tigecycline was lowest against K. pneumoniae (36.4%) and highest against E. coli.
DISCUSSION
WHO in February 2017, has published the list of pathogens for which new antibiotics are urgently needed and the list includes carbapenems resistant K. pneumoniae, E. coli, Acinetobacter spp. and Pseudomonas spp. among others [13] . These species are declared the most critical MDR pathogens and have become resistant to a number of antibiotic classes, including carbapenems, the best available antibiotics for treating multidrug resistant bacteria [14] .
This retrospective study was therefore aimed to find out the antibiogram profile of these particular pathogens against first and second line of antibiotics in our hospital. This study assumes importance in the light of continuously changing anti-microbial resistance trends with time. The comprehensive understanding about the local hospital antibiogram helps to eliminate nonperforming drugs and update the hospital based antibiotic policies. Further, these surveillance studies help to reduce the mortality and failures associated with empiric therapy.
The current study revealed that the susceptibility rates observed were less than 50% in IPD patients and less than 10% in ICU patients to all the first line antibiotics tested except ampicillinsulbactam, cefepime and gentamicin. The high level of resistance towards first line of antibiotics reported in IPD patients clearly indicate about the growing trend of multi-drug pathogens in the community acquired infections as well. Though a minimal amount of 10% susceptibility was reported to first line drugs in ICU patients, however it strongly indicates that all ICU patients don't suffer from MDR infections. A thorough check of medical history should be done before starting any therapy as some patients admitted in ICU could be suffering from community acquired infections and can be prescribed first line antibiotics. Moreover, a good sensitivity reported towards ampicillin-sulbactam, cefepime and gentamicin among first line drugs in both ICU and IPD patients suggests that their prescription can be increased in our hospital however on rotational basis to reduce the load on 2 nd line antibiotics. Though susceptibility rates towards 2 nd line antibiotics reported among IPD patients was higher than ICU patients but still, a good amount of resistance was observed towards all pathogens in IPD patients which is actually worrisome. The overall susceptibility to BL/BLI was 50-75% in IPD patients and carbapenem susceptibility was reported to be more than 75% except P. aeruginosa. In ICU patients, the BL/BLI susceptibility ranged between 20-60% and the carbapenem susceptibility was around 40% for K. pneumoniae and P. aeruginosa and 75% for E. coli and A. baumannii. Surprisingly, cefoperazone /sulbactam and cefepime/tazobactam performed comparatively better than carbapenems against Pseudomonas. Similar to our observations, Abdul et al. [15] have also reported that BL-BLI combinations performed better than carbapenems against pseudomonas.
They have reported a susceptibility rate of 32-77% to imipenem. Datta et al. [16] have reported carbapenem resistance of 7.87% among Enterobacteriaceae strains whereas carbapenem resistance rate ranging from 2% to 80% in various multi drug resistant organisms including E. coli, Klebsiella spp., Pseudomonas spp. and Acinetobacter spp. has been reported in a tertiary care hospital in Delhi [11] .
The antibiotic susceptibility reported by Abdul et al. [15] for different antibiotics tested is also almost similar to our pattern. Increase in carbapenems resistance has been linked with excessive carbapenem consumption. Hence selection pressure on carbapenems need to be reduced either by reducing their consumption by using alternative drugs or developing newer therapeutic options.
There are several publications about use of alternative agents for treating ESBL infections rather than carbapenems so as to reduce selection pressure without compromising clinical outcomes [17, 18] . Interestingly, the current data reveals a very important picture of comparable susceptibility of CSE-1034 to minocycline and amikacin. When compared to carbapenems, the susceptibility of CSE-1034 was comparable to carbapenems in Enterobacteriaceae, however the CSE-1034 performed better than carbapenems against P. aeruginosa and A. baumannii in both IPD and ICU patients. In case of amikacin, the performance of CSE-1034 was better than amikacin against K. pneumoniae in ICU patients. The rising carbapenem resistance worldwide has been an important concern and pressurizes the need to develop alternate drugs to reduce the selective pressure on this antibiotic class. Emerging evidence on the effectiveness of CSE-1034 could prove a very encouraging trend, helping clinicians to choose CSE-1034 rather than being overly dependent on carbapenems. And one of the best evidences comes in the form of clinical trial and post marketing surveillance studies. Data published from different centers have consistently reported high in vitro susceptibility and good in vivo performance of CSE-1034 against different MDR bacterial infections [19, 20, 21, 22, 23] . The sensitivity of colistin reported between 92-97% for different pathogens in this study is a matter of grave concern and needs to be addressed. Various centers located across India have reported a colistin sensitivity of 90-97% [24, 14] . The excessive consumption of colistin associated with the rise in MDR infections has probably led to rise in colistin resistance throughout the world [25, 26] .
A drug that has emerged with the potential of being used as carbapenem sparing options either empirically or as a de-escalation therapy includes CSE-1034. However, the less number of samples examined and a limited study period are the limitations of this study and should not be undermined. This kind of studies should be conducted on larger number of isolates to establish the exact antimicrobial trends. May be once we start using this CSE-1034 option at a larger scale, we can monitor clinical outcomes and come up with more conclusive evidence.
CONCLUSION
Overall, the rising carbapenem resistance among gram-negative strains as a consequence of excessive consumption of carbapenems is a matter of big concern. The appropriate use of 1 st line antibiotics in ICU patients can help to reduce the load on 2 nd line antibiotics. From the present study, it is evident that the use of ampicillinsulbactam, cefepime and gentamicin from first line drugs can be increased in our hospital however on rotational basis to reduce the load on 2 nd line antibiotics. Among 2 nd line drugs, CSE-1034 along with amikacin should be an empirical choice of treatment for bacterial infections where the 1st line drugs are suspected to fail and the need of carbapenems arises. Considering the value of carbapenem and colistin as the last option for MDR bacterial infections, irrational prescription of these drugs should be stopped. Moreover, these types of studies should be conducted in regular to monitor the changing local susceptibility patterns.
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